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SUMMARY STATEMENT 
Here, we provide evidence that alternative isoforms can substantially contribute to expanding 
the functionality of deubiquitylating enzymes, hence allowing them to regulate the multitude 
of intracellular ubiquitylation events.  
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ABSTRACT 
Protein ubiquitylation is a dynamic post-translational modification that can be reversed by 
deubiquitylating enzymes (DUBs). It is unclear how the small number of ~100 DUBs present 
in mammalian cells regulates the thousands of different ubiquitylation events. Here we 
analysed annotated transcripts of human DUBs and find ~300 ribosome-associated transcripts 
annotated as protein coding, which thus increase the total number of DUBs. Using USP35, a 
poorly studied DUB, as a case study we provide evidence that alternative isoforms contribute 
to the functional expansion of DUBs. We show the existence of two different USP35 
isoforms that localise to different intracellular compartments and have distinct functions. Our 
results reveal that isoform 1 is an anti-apoptotic factor that inhibits staurosporine- and TNF-
related apoptosis inducing ligand (TRAIL)-induced apoptosis. In contrast, USP35 isoform 2 
is an integral membrane protein of the endoplasmic reticulum (ER) present also at lipid 
droplets. Manipulations of isoform 2 levels cause rapid ER stress likely through deregulation 
of lipid homeostasis and lead to cell death. Our work highlights how alternative isoforms 
provide functional expansion of DUBs and sets directions for future research. 
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INTRODUCTION 
Covalent attachment of ubiquitin to target proteins, or ubiquitylation, regulates many critical 
intracellular processes such as signal transduction, protein turnover and trafficking. 
Ubiquitylation is achieved through a sequential action of E1 activating, E2 conjugating and 
E3 ligating enzymes, and can be reversed by deubiquitylating enzymes or deubiquitinases 
(DUBs) (Hershko and Ciechanover, 1998). Ubiquitylation usually occurs on lysine residues 
of a substrate protein. Importantly, one of the seven internal lysines or the N-terminal 
methionine of ubiquitin can serve as an attachment site for another ubiquitin, thus forming 
ubiquitin chains (polyubiquitin) whose linkage type determines the biological outcome of 
ubiquitylation (Yau and Rape, 2016) 
The importance of protein ubiquitylation and deubiquitylation is underscored by the fact that 
deregulation of these processes has been linked to the pathogenesis of many human diseases 
such as cancer, and neurodegenerative and metabolic disorders (Heideker and Wertz, 2015; 
Popovic et al., 2014). In many cases, such detrimental outcomes stem from deregulation of 
key signalling pathways that are normally controlled by the ubiquitin system. For example, 
several DUBs have been implicated in the regulation of cell death either through controlling 
the stability of various pro- and anti-apoptotic factors or by regulating the formation of 
essential signalling complexes (Engel et al., 2016; Jeong et al., 2017; Lee et al., 2015; Mahul-
Mellier et al., 2012; Mei et al., 2011; Schwickart et al., 2010; Weber et al., 2016).  
Considering their profound roles in regulating cell fate and function we still know 
surprisingly little about the precise functions and substrates of many DUBs. Further, it is 
intriguing that a relatively small number of DUBs (~100 predicted to exist based on the 
human genome sequence) can regulate at least ~20,000 ubiquitin-modified sites that can be 
currently detected at steady-state conditions in mammalian cells (Clague et al., 2015; Kim et 
al., 2011; Udeshi et al., 2013). Whilst we are still far from understanding how this is 
achieved, several potential modes of expanding the functionality of DUBs have been 
proposed. These include alternative subcellular localization of DUBs, regulation by 
interacting proteins and post-translational modifications. An unappreciated mechanism is the 
expansion of DUB functionality via alternative splicing, which provides a way to increase the 
total number of DUBs that can perform distinct functions (Leznicki and Kulathu, 2017). 
However, with few exceptions, the presence and specific functions of alternative DUBs 
isoforms have been almost completely neglected. 
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In order to understand to what extent alternative isoforms contribute to the functional 
expansion of DUBs, we analysed a recent dataset of ribosome-associated transcripts from 
HEK293 cells (Floor and Doudna, 2016). Strikingly, we found that ~300 DUB transcripts 
annotated as protein coding associate with translating ribosomes in human cells. To address if 
DUB isoforms perform non-redundant functions, we chose a poorly studied DUB, USP35, as 
a case study. Here, we characterised USP35 using biochemical, structural and cell biological 
approaches. Intriguingly, we detect at least two different USP35 isoforms at the endogenous 
level that localise to distinct intracellular compartments. In contrast to isoform 1, which is a 
soluble protein, isoform 2 is a novel integral membrane protein that localises to the ER and 
lipid droplets. Remarkably, isoform 2 expression induces rapid ER stress most likely because 
of perturbed lipid homeostasis and leads to cell death. Isoform 1 has a distinct function and 
acts as an anti-apoptotic factor that inhibits TNF-related apoptosis inducing ligand (TRAIL)- 
and staurosporine-induced apoptosis. Our results highlight how products of a single DUB-
encoding gene can have contrasting functions.  
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RESULTS 
Alternative isoforms expand the number of DUBs 
A number of transcripts associate with translating ribosomes in HEK293 cells, suggesting 
widespread production of alternative isoforms (Floor and Doudna, 2016). We analysed the 
results of this high-throughput study to get insights into the extent to which the functionality 
of DUBs could be expanded by the presence of DUB isoforms. Strikingly, we find that in 
HEK293 cells there are ~500 ribosome-associated DUB transcripts, of which ~300 are 
annotated as protein coding (Table S1). The number of protein coding DUB transcripts is 
likely an underestimation because mRNAs coding for some of the known DUBs such as 
OTUD6A and USP26 were not detected in the above-mentioned study (Floor and Doudna, 
2016). Further, this estimation is based on HEK293 cells and given that isoforms are 
expressed in a tissue-specific manner (Buljan et al., 2012; Ellis et al., 2012; Yang et al., 
2016), it is likely that the total number of DUB isoforms expressed is even greater. As many 
of the DUB transcripts lack annotated 5’ or 3’ ends, DUB-centred transcriptomics analyses 
will be required to define the precise boundaries of these isoforms. Importantly, isoform-
specific peptides were detected for at least some of these putative isoforms confirming their 
existence in living cells (Wilhelm et al., 2014).  
 
USP35 is an active, ubiquitin linkage type-promiscuous DUB 
To explore how alternative isoforms expand DUB function, we here studied USP35, a 
member of the ubiquitin specific protease (USP) DUB family. Importantly, transcripts with 
annotated 5’ and 3’ ends coding for three different USP35 isoforms with intact catalytic 
domain were shown to associate with translating ribosomes (Floor and Doudna, 2016) (Fig 
1A). The different USP35 isoforms are: full length (USP35iso1), an isoform with an N-
terminal truncation of 269 residues (USP35iso2) and one lacking 432 residues at the N-
terminus (USP35iso3). Furthermore, high-throughput proteomic experiments identified unique 
acetylated N-terminal peptides specific for USP35iso1 and USP35iso2 (Wilhelm et al., 2014). 
USP35 is a poorly studied DUB suggested to play a role in mitophagy (Wang et al., 2015) 
and as a tumour suppressor (Liu et al., 2015). The latter finding is, however, at odds with 
reports showing that USP35 is amplified in a number of cancers, particularly breast and 
ovarian ((Chin et al., 2007) and www.cbioportal.org).  
USP35 is characterised by the presence of a USP catalytic domain where cysteine 450 is the 
active site (Fig 1A). Similar to other USP DUBs that have insertions within their catalytic 
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domains, USP35 also has a long highly-charged ~150 residue loop insertion in its USP 
domain that spans residues 604-753 and is predicted to be unstructured (Ye et al., 2009). 
Based on the crystal structure of the N-terminal fragment of a closely related DUB, USP38 
(Shen et al.) (PDB: 4RXX), it can be expected that USP35 also contains N-terminal HEAT 
repeats (Fig 1A), a motif known to mediate protein-protein interactions.  
In order to investigate if USP35 is an active enzyme, we expressed and purified full-length 
human USP35iso1. When tested for enzymatic activity against tetraubiquitins of defined 
linkage types, USP35 showed promiscuous activity and cleaved several linkages of which 
Lys11-, Lys33-, Lys48- and Lys63-linked polyubiquitin were cleaved most efficiently (Fig 
1B). Such promiscuity is often found amongst members of the USP family of DUBs whose 
selectivity seems to be determined by a substrate rather than ubiquitin linkage type (Faesen et 
al., 2011).  
To understand USP35 at the molecular level we attempted to crystallise catalytically inactive 
(C450S mutant) USP35423-944, the fragment that spans the catalytic domain shared by all three 
isoforms, in complex with Lys48-linked diubiquitin. Since the full length catalytic domain 
was refractory to crystallization, we speculated that removing the disordered loop insertion 
within the catalytic domain would result in diffracting crystals. Indeed, we obtained crystals 
of the catalytic domain lacking this loop in complex with Lys48 diubiquitin that diffracted to 
1.8Å (Fig 1C). The structure was solved by molecular replacement and refined to the 
statistics shown in Table S2. Importantly, bacterially purified catalytic domain of USP35 
lacking the loop insertion shows similar activity and ubiquitin linkage type preference as the 
wild-type catalytic domain (Fig S1). Surprisingly, we could only detect a single ubiquitin in 
complex with USP35, which might result from the residual DUB activity of the C450S 
mutant used (data not shown). Hence, the structure represents USP35 in complex with the 
distal ubiquitin. The crystal structure of USP35 reveals a typical USP domain architecture 
that superposes well onto the structures of previously crystallised USP domains (Figs 1C and 
S2). Clearly defined subdomains referred to as thumb, palm and fingers can be observed in 
the structure (Fig 1C) (Yin et al., 2015). The bulk of ubiquitin until Arg72 is clasped between 
the thumb, palm and fingers subdomains by a strong network of hydrophobic, ionic and 
hydrogen bonds (Figs 1C and S3).  The cation-π and aromatic-aromatic interactions between 
the fingers sub-domain and the ubiquitin molecule stabilise the complex (Fig S3). Clear 
electron density is visible for the catalytic triad of USP35, composed of Cys450, His862 and 
Asp895 (Figs 1C and S3E).  
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USP35 shows isoform-specific subcellular localisation 
Since the three USP35 isoforms all contain an intact catalytic domain (Fig 1A), we wondered 
if the differences in the N-terminal region regulate their intracellular localisation. To address 
this possibility, we analysed the subcellular localisation of C-terminally GFP-tagged USP35 
isoforms (Fig 2A). Strikingly, we observed that the intracellular distribution of the proteins 
analysed was isoform-specific. While USP35iso1 and USP35iso3 display a rather diffuse 
staining, USP35iso2 shows a reticular pattern, suggestive of endoplasmic reticulum (ER) 
localisation. Importantly, since the C-terminus of all isoforms analysed is identical, the 
differences observed in the staining pattern do not result from protein tagging. To determine 
which subcellular compartment USP35iso2 resides in, we performed co-localisation 
experiments that showed a clear overlap in the staining pattern of USP35iso2 and an 
endogenous ER marker, BAP31 (Ng et al., 1997) (Fig 2B), confirming that USP35iso2 
localises to the ER.  
Interestingly, in addition to the reticular ER staining, USP35iso2 forms doughnut-like 
structures that could potentially correspond to protein aggregates, intracellular vesicles or 
lipid droplets (Fig S4A). Interestingly, in a number of cells such doughnut-like staining of 
USP35iso2 was predominant, in particular when the detergent permeabilisation step during 
sample preparation was omitted. This suggests that these are lipid-based structures such as 
lipid droplets. Lipid droplets are intracellular organelles that originate from the ER and serve 
as primary storage sites of neutral lipids such as triglycerides and cholesterol esters (Welte, 
2015). Given our finding that USP35iso2 localises to the ER and that the USP35iso2-positive 
doughnut-like structures are likely detergent-sensitive, we investigated if they correspond to 
lipid droplets. Indeed, USP35iso2 co-localises with the dye LipidTox that stains lipid droplets 
(Fig 2C, top panel) and this co-localisation is even more pronounced in cells treated with 
oleic acid (Fig 2C, bottom panel), a condition that induces the formation and accumulation of 
lipid droplets (Eastman et al., 2009). These data indicate that in addition to ER localisation, 
USP35iso2 is also present at lipid droplets making it, to the best of our knowledge, the first 
lipid droplet-localising DUB.  
 
USP35 isoform 2 is an integral ER membrane protein 
ER localisation of proteins results either from their integration into the lipid bilayer or 
peripheral binding to other proteins or lipids. To understand how ER targeting of USP35iso2 is 
achieved, we analysed its amino acid sequence. Two potential, albeit relatively hydrophilic, 
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transmembrane domains (TMDs) predicted to span residues 317-337 and 797-815 
(numbering based on iso1) were detected (Hessa et al., 2007). Helix 797-815 is located 
within the USP domain suggesting that it does not mediate ER localisation. The potential 
TMD comprising residues 317-337 is more hydrophobic and also predicted by an alternative 
TMD prediction algorithm, TMpred 
(http://www.ch.embnet.org/software/TMPRED_form.html). Prediction algorithms do not 
indicate an N-terminal signal peptide in USP35iso2 amino acid sequence and hence the 
predicted transmembrane domain could also act as an ER targeting signal (Shao and Hegde, 
2011). Indeed, a short USP35 fragment, USP35245-432, still co-localises with BAP31 
indicating that the ER targeting motif is located within this sequence in agreement with the 
prediction for a putative TMD (Fig 2D).  
To experimentally address if USP35iso2 is an integral membrane protein, we performed 
protease protection experiments using U2OS FlpIn cells expressing USP35 isoforms fused to 
GFP either at the N- or C-terminus. Cells were treated with digitonin that selectively 
permeabilises the cholesterol-rich plasma membrane while maintaining the integrity of the 
cholesterol-poor ER membrane. This in turn allows for trypsin-mediated digestion of 
cytosolically exposed protein regions whilst leaving the ER luminal proteins intact due to the 
inability of the protease to access the ER lumen. When calnexin (CNX), a model ER 
membrane protein, was tested, addition of trypsin resulted in the cleavage of its cytosolic 
portion as assessed by the increase in its electrophoretic mobility (Fig 3A). When the same 
analysis was carried out for GFP-tagged USP35 isoforms, an anti-GFP antibody-reactive, 
protease-protected species was apparent only when N-terminally tagged USP35iso2 was 
expressed (Fig 3A, lane 6, red dot). Importantly, the ~37 kDa size of this fragment 
corresponds to the size of GFP-tagged USP35270-360 that would be generated by trypsin 
cleavage if residues 317-337 constitute the TMD (~27 kDa GFP tag and ~10 kDa mass of 
amino acids 270-360). No trypsin-resistant fragments were observed when iso1 or C-
terminally tagged iso2 were used indicating complete proteolysis of their GFP tag (Fig 3A). 
The results obtained using the protease protection assay clearly show that iso2 is an integral 
membrane protein with its N-terminus in the ER lumen. 
To further confirm our results, we used an assay that monitors N-glycosylation of ER-
destined proteins (Borgese et al., 2001; Leznicki et al., 2010). Importantly, N-glycosylation 
takes place in the ER lumen and hence can be used as an independent read-out for the luminal 
localisation of a protein or its portion. Hence, we fused USP35iso2 to a short peptide derived 
from bovine rhodopsin (OPG) that contains two N-glycosylation sites (Borgese et al., 2001) 
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and transiently expressed it in U2OS FlpIn cells. Consistent with the results of the protease 
protection assay, N-glycosylation of iso2 was only observed when the OPG tag was placed at 
its N-terminus as assessed by the change in the electrophoretic mobility following 
endoglycosidase H (EndoH) treatment (Fig 3B, lanes 1 and 2, OPG-iso2 panel). Consistent 
with amino acids 317-337 acting as the TMD, a short fragment of USP35, USP35270-432, is 
efficiently N-glycosylated when fused to the OPG tag (Fig 3C). Interestingly, in this case the 
orientation of the TMD is random as evidenced by the modification of both the N- and C-
terminally tagged USP35270-432. This is most likely caused by the small size of the fragment 
used and suggests that the C-terminal portion, i.e. the catalytic domain may play a role in 
dictating the topology.  
The ER targeting motif of USP35iso2 is also present in iso1 yet we found no evidence of its 
ER membrane integration. We speculated that this might be caused by the presence of the 
intact N-terminal HEAT repeats in iso1 that are truncated in iso2 (Fig 1A). To investigate if 
the length of the HEAT repeats affects ER integration of USP35 we generated truncated 
variants of USP35 bearing an N-terminal OPG tag and assessed their integration into the ER 
membrane using N-glycosylation as a read-out. Indeed, we observed that whilst USP35iso2 
and USP35180-1018 are efficiently inserted into the ER lipid bilayer, increasing the length of 
the N-terminal HEAT repeats abolishes USP35 integration into the ER membrane (Fig 3D). 
This argues for the role of HEAT repeats in limiting ER integration of USP35iso1. Taken 
together, we conclude that USP35iso1 is a soluble, predominantly cytosolic protein whilst 
USP35iso2 is an integral membrane protein of the ER with its N-terminus in the ER lumen and 
C-terminus together with the USP domain facing the cytosol (Fig 3E). Importantly, the 
sequence of the proposed transmembrane region is highly conserved in vertebrates (Fig 3E).  
It was previously reported (Buljan et al., 2012; Ellis et al., 2012; Yang et al., 2016) that the 
relative abundance of protein isoforms differs depending on the cell type and tissue analysed, 
and we wondered if the same applied to USP35. We therefore raised antibodies that recognise 
the N-terminal (AbN), middle (Ab2) or C-terminal (AbC) portions of USP35 (Fig 1A) and 
used AbC (that should recognise both isoforms 1 and 2) to screen a panel of different cell 
lines (Fig S4B). In all cell lines tested, we could clearly detect a protein species that we 
identify as USP35iso1 based on its electrophoretic properties (Fig S4B) and sensitivity to 
siRNA-mediated depletion (Fig S4C) 
Interestingly, in two cell lines, pancreatic cancer cell line HPAF-II and lung cancer cell line 
NCI-H1435, we could also detect an additional USP35 protein species that could correspond 
to USP35iso2 based on its electrophoretic mobility (Fig S4B). To verify if this protein is 
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indeed USP35iso2, we tested its localisation by performing subcellular fractionation of HPAF-
II cells (Fig 3F). To aid in the assignment of USP35 isoform bands we used lysates of HPAF-
II cells transfected with plasmids encoding untagged USP35iso1 and USP35iso2. Our results 
showed that USP35iso1 is predominantly cytosolic (Fig 3F). Strikingly, we could also detect a 
protein species with electrophoretic migration identical to that of ectopically expressed 
untagged USP35iso2 (Fig 3F, “USP35 long exp.” panel). Importantly, as expected for an 
integral membrane protein, this anti-USP35 antibody-reactive species was recovered 
exclusively in the membrane fraction (Fig 3F, “USP35 long exp.” panel). To further confirm 
the existence of USP35iso2 at the endogenous level we immunoprecipitated USP35 from 
HPAF-II cells (Fig 3G). This approach allowed us to recover two USP35 species that migrate 
with similar electrophoretic mobility as isoforms 1 and 2 (Fig 3G). Based on their 
electrophoretic properties, reactivity with three distinct anti-USP35 antibodies and results of 
the subcellular fractionation experiments we infer that these two species correspond to 
USP35 isoforms 1 and 2.  
 
USP35 isoform 2 induces ER stress and apoptosis 
We next wanted to understand if USP35 isoforms 1 and 2 perform isoform-specific functions. 
Intriguingly, when investigating the intracellular localisation of USP35 we noticed that cells 
expressing USP35iso2 in many cases showed altered BAP31 staining that resembled 
aggregate-like structures (Fig 4A). To test if this was due to a general aggregation of the ER 
membrane, we monitored the staining for signal peptide peptidase (SPP), another integral ER 
membrane protein. Localisation of SPP was unchanged suggesting that the punctate staining 
of BAP31 was specific (Fig 4A). Formation of BAP31 punctae reflects BAP31 cleavage by 
caspase-8 during apoptosis (Maatta et al., 2000), and expression of USP35iso2 results in 
BAP31 cleavage as indicated by its increased electrophoretic mobility (Fig 4B). Further, 
BAP31 cleavage is accompanied by activation of caspase-8 and caspase-3 (Fig 4B). 
Expression of USP35iso2 also causes ER stress that is evident by increased levels of the ER 
luminal chaperone, BiP (Fig 4B). Importantly, a control ER-membrane localising construct, 
GFP fused to the ER targeting sequence of cytochrome b5 (GFP-b5) (Bulbarelli et al., 2002), 
does not induce the same phenotype indicating the specificity of USP35iso2 action (Fig 4B, 
lanes 1 and 2). Consistent with the observed apoptotic events, overexpression of USP35iso2 
blocks cell proliferation (Fig 4C).  
ER stress initiates signalling events that result in improved folding capacity of the ER, for 
example, by upregulating the expression of luminal chaperones and blocking general protein 
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translation (Tabas and Ron, 2011). Unresolved ER stress, however, triggers apoptosis 
through the action of protein kinase PERK and its target CHOP, a transcription factor. CHOP 
activates transcription of several pro-apoptotic genes including death receptor 5 (DR5), a cell 
surface receptor for ligands such as TNF related apoptosis inducing ligand (TRAIL) that 
stimulate the extrinsic apoptotic pathway (Lu et al., 2014). Importantly, ER stress induced, 
CHOP-mediated upregulation of DR5 has been proposed to activate caspase-8 leading to 
apoptosis (Lu et al., 2014). However, the precise function of caspase-8 in ER stress induced 
cell death is debated with some studies arguing against such a role for caspase-8 (Glab et al., 
2017). In order to establish if USP35iso2 expression also upregulates markers of ER stress 
induced apoptosis we monitored protein levels of CHOP and DR5 following USP35iso2 
expression (Fig 4D). Inducing USP35iso2 expression for 24h resulted in significantly elevated 
levels of CHOP and DR5 and this effect was blocked by simultaneous treatment with 
GSK2606414, an inhibitor of PERK (Axten et al., 2012) (Fig 4D). Importantly, in addition to 
U2OS FlpIn cells used so far, we observe the same role of USP35iso2 in inducing ER stress 
and cell death in HeLa FlpIn cells (Fig. 4E), indicating that USP35iso2 function is conserved. 
Interestingly, while caspase-3 is clearly activated in HeLa FlpIn cells expressing USP35iso2, 
no processing of caspase-8 was detected, which is at odds with our findings using U2OS 
FlpIn cells. This is, however, consistent with conflicting reports about the role of caspase-8 in 
inducing cell death during conditions of ER stress (Glab et al., 2017; Lu et al., 2014). We 
then sought to understand the kinetics of USP35iso2-mediated ER stress. To this end, 
expression of C-terminally tagged USP35iso2 was induced and ER stress monitored over time. 
Strikingly, BiP expression was already elevated after 10h induction of USP35iso2, which is 
only 4h after the protein is detectable by Western blotting (Fig 4F). To further assess the 
specificity of USP35iso2-induced ER stress and apoptosis we created U2OS FlpIn cell line 
expressing GFP-tagged USP19, the only reported integral membrane DUB of the ER. 
Importantly, expression of USP19 at levels comparable to USP35iso2 did not induce apoptosis 
or detectable ER stress (Fig 4G). Collectively, our results suggest that ectopic USP35iso2 
expression causes specific and rapid ER stress and apoptosis.  
 
USP35iso2-mediated ER stress results from misregulated lipid homeostasis and is 
uncoupled from apoptosis induction 
Given the lipid droplet localisation of USP35iso2 and links between the ER and lipid 
metabolism we speculated that USP35iso2 induces ER stress and cell death by interfering with 
some aspects of lipid homeostasis. Because lipid droplets are the primary storage sites for 
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cholesterol esters we investigated if USP35iso2 induced ER stress and apoptosis might result 
from aberrations of cholesterol metabolism. Hence, we followed the effect of USP35iso2 
expression on ER stress in the presence of mevastatin and lovastatin, inhibitors of 3-hydroxy-
3-methyl-CoA reductase (HMGCR), a rate-limiting enzyme of cholesterol biosynthesis. 
Strikingly, we observed that inhibiting HMGCR significantly reduces USP35iso2-induced ER 
stress as measured by BiP upregulation (Figs 5A and B). Importantly, inhibiting cholesterol 
biosynthesis had no effect on ER stress initiated by disrupting ER calcium homeostasis (Fig 
5A). Taken together, these results imply that inhibiting cholesterol synthesis specifically 
interferes with early steps of ER stress induced by USP35iso2 rather than downstream events 
general to ER stress response. Surprisingly, inhibiting cholesterol synthesis prevents 
USP35iso2-induced ER stress but does not impede caspase-8 and caspase-3 activation, 
suggesting that ER stress and apoptosis induced by USP35iso2 could be unrelated events. To 
exclude the possibility that the inhibitory effect of statins was an indirect consequence of 
depleting cholesterol, we expressed USP35iso2 in U2OS FlpIn cells grown in media 
containing lipoprotein deficient serum (LPDS) and assessed ER stress by monitoring BiP 
levels (Fig S5A). We found that while LPDS treatment efficiently lowered cellular 
cholesterol levels as measured by upregulation of low density lipoprotein receptor (LDLR), it 
did not block USP35iso2-induced ER stress. Hence, we conclude that cholesterol per se is not 
required for the induction of ER stress by USP35iso2 but rather USP35iso2 expression 
interferes with lipid homeostasis possibly by affecting the cholesterol and/or isoprenoids 
biosynthetic route. 
To further explore the links between USP35iso2-mediated ER stress and apoptosis we 
expressed various USP35iso2 truncations and assessed their capacity to induce ER stress and 
apoptosis. We observed that USP35iso2 lacking the insertion loop within the catalytic domain 
(Fig 1A) was more efficient at inducing apoptosis than the wild-type protein despite lower 
capacity to induce ER stress (Fig 5C). Importantly, expression of USP35iso2 lacking the 
predicted ER luminal residues (amino acids 270-316) no longer triggered ER stress and 
apoptosis (Fig 5C). Whilst it is unclear why deletion of the insertion loop from USP35iso2 
increases its capacity to induce apoptosis yet lowers the extent of ER stress that it induces, 
this result again shows that apoptosis is not a simple consequence of ER stress caused by 
USP35iso2 expression. Hence, these observations suggest that the ER stress and apoptosis 
induced by USP35iso2 are two distinct phenomena.  
To further investigate this possibility, we tested the effect of the PERK inhibitor 
GSK2606414 on cells expressing USP35iso2 (Fig S5B). Again, we found that GSK2606414 
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almost completely blocked ER stress induced by USP35iso2 (Fig S5B, compare lanes 1 and 4, 
see also Fig 4D).  Despite the loss of ER stress, the cells still exhibited apoptosis albeit to a 
lesser extent than in control cells. Interestingly, a recent study showed that GSK2606414 is 
also a potent inhibitor of RIPK1-mediated apoptosis and necroptosis (Rojas-Rivera et al., 
2017).  Hence, an “off-target” effect of GSK2606414 on apoptosis independent of ER stress 
is likely and could explain the apparent discrepancy between the effect of GSK2606414 and 
statins on USP35iso2-induced apoptosis. Nonetheless, the fact that GSK2606414 failed to 
completely block USP35iso2-induced apoptosis lead us to conclude that ER stress and 
apoptosis induced by USP35iso2 are unrelated events.  
To investigate if the ability of USP35iso2 to induce ER stress and apoptosis is linked to ER 
membrane/lipid droplet localisation we performed subcellular fractionation and pull-down 
assays from cells expressing GFP-tagged wild-type USP35 and its variants lacking either the 
insertion loop or luminal residues. Indeed, we observed that variants that induce ER stress 
and apoptosis efficiently co-fractionate with cellular membranes (Fig 5D) and interact with 
lipid droplet-associated protein, PLIN2 (Fig 5E). Such shared requirements for membrane 
localisation and lipid droplet association are in agreement with previous reports showing that 
localisation to these two organelles can be mediated by the same hydrophobic domain 
(Bersuker et al., 2018; Zehmer et al., 2008). USP35iso2 lacking residues 270-316 only weakly 
associated with membranes (Fig 5D) suggesting that these residues contribute to the ER 
membrane localisation of USP35iso2. These findings demonstrate the importance of 
membrane/lipid droplet localisation of USP35iso2 for the induction of ER stress and apoptosis. 
To further verify this conclusion, we fused GFP-tagged USP35 fragments to the first 61 
residues of SPP that encompass its first transmembrane domain with a topology that ensures 
cytosolic localisation of USP35 catalytic domain. Strikingly, we observed that such enforced 
ER membrane localisation of soluble fragments of USP35 spanning residues 338-1018 and 
433-1018 (which corresponds to isoform 3) was sufficient to induce both ER stress and 
apoptosis (Fig 5F). However, targeting GFP alone to the ER using the same tag does not 
produce the effects observed with USP35. Hence, ER membrane anchoring of USP35 
catalytic domain is sufficient to induce ER stress and apoptosis.  
 
USP35iso1 is an anti-apoptotic protein 
In order to compare the functions of isoforms 1 and 2 of USP35, we tested the effect of their 
overexpression on the induction of ER stress and apoptosis. Consistent with our previous data 
(Fig 4) increased levels of USP35iso2 led to the induction of apoptosis (Fig 6A). In contrast, 
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USP35iso1 did not induce the same phenotype (Fig 6A) suggesting distinct functions for these 
two isoforms, in line with their distinct intracellular localisation.  
The D. melanogaster orthologue of USP35 and USP38, DUBAI, has previously been shown 
to be an anti-apoptotic protein (Yang et al., 2014). To test if USP35iso1 has the same function 
in mammalian cells, we monitored apoptosis in HEK293 cells overexpressing USP35iso1 
following the apoptotic stimulus, TRAIL, by monitoring cleavage of caspase-8, the main 
initiator caspase of the extrinsic apoptotic pathway. Compared to control cells, cells 
expressing increased levels of USP35iso1 exhibit delayed processing of caspase-8 during 
TRAIL-induced apoptosis (Fig 6B). Importantly, this anti-apoptotic effect required the 
catalytic activity of USP35iso1 (Fig 6B, lanes 9-16 and 17-24). Since overexpression has an 
anti-apoptotic effect, we posited that depletion of USP35 would result in an opposite effect, 
i.e. sensitise cells to apoptotic stimuli. To address this possibility, we deleted USP35 using 
CRISPR/Cas9-mediated gene editing. Indeed, we observed that USP35 knock-out cells are 
substantially more sensitive to TRAIL-induced apoptosis as assessed by activation of 
caspase-8 (Fig 6C). Consistent with such increased processing of caspase-8 upon USP35 
depletion, USP35 knock-out cells are significantly more sensitive to TRAIL treatment (Fig 
6D). Further, we also observed increased sensitivity of USP35 knock-out clones to 
staurosporine-induced apoptosis as assessed by activation of caspase-3 (Fig 6E). Our results 
reveal that in contrast to USP35iso2, isoform 1 has an anti-apoptotic function. 
A common feature of many anti-apoptotic proteins such as inhibitors of apoptosis proteins 
(IAPs) is their proteolytic processing during apoptosis (Hao et al., 2004; Hornle et al., 2011), 
which leads to their inactivation and allows for progression of cell death. We therefore 
wanted to investigate if iso1 of USP35 is also a subject of such processing. To test this 
possibility, we induced apoptosis with staurosporine in HeLa cells that express USP35iso1 at 
relatively high levels (Fig S4B). Strikingly, endogenous USP35 was efficiently cleaved 
during staurosporine-induced cell death (Figs S6A, B). The cleaved fragments could be 
recovered by immunoprecipitation using antibodies raised against the N- or C-terminal parts 
of USP35 with the N-terminal fragment being ~85 kDa and the C-terminal one ~30 kDa (Fig 
S6B). This USP35 proteolysis could be blocked by zVAD-fmk, a pan-caspase inhibitor, 
suggesting that the processing is mediated by caspase(s) (Figs S6A, B). Indeed, in vitro 
caspase cleavage assay indicates that proteolysis of USP35 is mediated by the executioner 
caspases, caspases -3 and/or -6 (Fig S6C). Mass spectrometric analyses identified D743 as 
the cleavage site, a finding consistent with the size of USP35 fragments observed in HeLa 
cells undergoing apoptosis (Figs S6A, B). Indeed, mutation of the cleavage site D743 to 
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alanine completely blocked USP35 proteolysis during staurosporine-induced apoptosis (Fig 
6F). In summary, our findings reveal that USP35iso1 is an anti-apoptotic protein and suggest a 
model where proteolytic cleavage by caspases at D743 within the USP35 catalytic domain 
inactivates the DUB and thereby its anti-apoptotic function. 
 
USP35 isoform-specific interactome 
The fact that USP35iso1 is anti-apoptotic and USP35iso2 pro-apoptotic suggests that these two 
proteins might exert their effects by differentially regulating a common interacting partner(s). 
To investigate this possibility, we identified the binding partners of both USP35 isoforms 
using HEK293 FlpIn cell lines expressing USP35 isoforms C-terminally tagged with 
BirAR118G. This allows for the use of the BioID methodology capable of identifying 
interactions transient in nature or occurring in organelles resistant to conventional 
immunoprecipitation techniques (Roux et al., 2012). In agreement with distinct subcellular 
localisation of USP35iso1 and USP35iso2 we found that the GO terms associated with their 
interacting partners are differently enriched (Fig 7A). Hence, USP35iso2 preferentially 
interacts with proteins linked to intracellular membranes, in particular the ER. In contrast, 
USP35iso1 interacts predominantly with cytosolic and centrosomal proteins. Importantly, 
USP35iso2 interacted with a number of enzymes linked to lipid metabolism (HMGCR, 
CYP51A1, AGPAT4) and protein quality control (TRIM13, BAG6, UBE2J1, UBR3) (Fig 7B 
and Table S3). Only ~15% of the total binding partners were shared by the two USP35 
isoforms confirming their distinct functions. Interestingly, among the common interacting 
proteins was BIRC6, a known IAP (Bartke et al., 2004; Hao et al., 2004), which could 
potentially be targeted by both USP35 isoforms. To test if USP35 isoforms act on the same 
pathway regulating apoptosis we tested if USP35iso1 can inhibit USP35iso2-induced apoptosis. 
Cells expressing USP35iso2 in an inducible manner were transfected with USP35iso1 at the 
time of USP35iso2 induction, and upregulation of BiP and caspase-3 cleavage were monitored. 
This revealed that USP35iso1 cannot block USP35iso2-induced apoptosis (Fig S6D) suggesting 
that the two isoforms regulate different aspects of apoptosis.   
 17
DISCUSSION 
In the current study we show that mammalian cells express at least two USP35 isoforms that 
localise to distinct subcellular compartments and have distinct functions. Isoform 1 is an anti-
apoptotic protein that regulates progression of TRAIL- and staurosporine-induced apoptosis. 
At the same time, isoform 2 is a novel integral membrane protein that localises to the ER and 
lipid droplets, its overexpression perturbs lipid homeostasis and causes ER stress and 
apoptosis.  
Interestingly, until now USP19 was the only known DUB that is an integral ER membrane 
protein (Hassink et al., 2009). USP35iso2 that we identified in this study becomes the second 
integral ER membrane DUB. Intriguingly, just like we observe for USP35 also USP19 exists 
in at least two forms, cytosolic and ER membrane-localised, that have non-redundant 
functions (Hassink et al., 2009; Lee et al., 2016). Moreover, USP35iso2 is, to the best of our 
knowledge, the first lipid droplet associated DUB. Lipid droplets perform important functions 
that extend beyond lipid storage and mobilisation. These include protein sequestration and 
degradation evidenced by the presence of ubiquitin-conjugating machinery at lipid droplets 
(Klemm et al., 2011; Spandl et al., 2011; Welte, 2015). Moreover, lipid droplet dynamics is 
also regulated by protein ubiquitylation (Eastman et al., 2009) and hence our discovery of a 
lipid droplet associated DUB opens new avenues of research. 
Surprisingly, USP35iso1 and USP35iso2 both contain the same ER membrane targeting motif 
yet we observe that only iso2 inserts into the ER lipid bilayer. Based on our data we postulate 
that the N-terminal HEAT repeats present in iso1 but truncated in iso2 mediate either co-
translational folding or recruitment of interacting factors that prevent ER delivery of iso1. 
Indeed, the inhibitory effect of co-translational folding on protein translocation into the ER is 
well documented (Conti et al., 2014; Denzer et al., 1995). Removal of the N-terminal 269 
residues as seen in USP35iso2 would disrupt the HEAT repeat motif composed of consecutive 
alpha helices that form extensive contacts with each other. This in turn would allow for 
efficient ER targeting. Interestingly, addition of an N-terminal GFP tag to USP35iso2 does not 
block its integration into the ER membrane indicating that specific interactions of the N-
terminal portion of iso1 are required to prevent its ER delivery.  
Strikingly, we observe that ectopic expression of USP35iso2 induces rapid ER stress and 
apoptosis in different cell lines. We show that ER stress initiated by USP35iso2 can be 
attenuated by inhibition of the rate-limiting enzyme of cholesterol biosynthesis, HMGCR, 
suggesting that it most likely results from perturbed lipid homeostasis. Imbalance in lipid 
metabolism can alter the composition of the ER membrane causing “lipid bilayer stress” (Han 
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et al., 2010; Pineau et al., 2009; Promlek et al., 2011; Thibault et al., 2012) and our data 
suggest that USP35iso2 might contribute to this effect. Importantly, we also show that 
anchoring soluble fragments of USP35 to the ER membrane is sufficient to induce both ER 
stress and apoptosis. The precise mechanistic details behind USP35iso2-mediated ER stress 
remain to be uncovered. However, growing incidence of metabolic disorders linked to 
cholesterol metabolism and ER stress such as atherosclerosis warrants future studies on 
USP35iso2.  
Interestingly, our data indicate that the two phenotypes, ER stress and apoptosis, induced by 
USP35iso2 are unrelated. Intriguingly, our transcriptomics analyses indicate that total mRNAs 
coding for USP35iso2 is more abundant than mRNA encoding iso1 in cell lines and human 
tissues. However, at the protein level, USP35iso1 is the predominant USP35 species (Figs 
S4B, S7A, B). It is tempting to speculate that protein levels of USP35iso2 are kept low in 
order to avoid ER stress and apoptosis. However, the abundance of USP35iso2 mRNA would 
allow for its rapid translation in response to a yet unknown stimulus. Because USP35iso2 
levels do not appear to increase following proteasome inhibition with MG132 (Fig S4C), we 
think that USP35iso2 protein levels are controlled at the translation step rather than through 
regulated protein degradation. A similar relief of miRNA-inhibited protein translation during 
conditions of stress has been reported for the cationic amino acid transporter 1 (CAT-1) 
(Bhattacharyya et al., 2006), establishing a paradigm for such a mechanism. Interestingly, 
USP35 is amplified in a number of cancers ((Chin et al., 2007) and Table S4 for USP35 copy 
number in selected cancer cell lines) and our analysis indicates that also in most primary 
tumours, USP35iso2 is preferentially transcribed (Fig S7C). Identification of stimuli that 
induce USP35iso2 production at the protein level will be of key importance for deciphering its 
molecular function. 
We show that in contrast to USP35iso2, USP35iso1 is a novel anti-apoptotic protein. This is 
evident using both overexpression and knock-out systems and assaying apoptosis in response 
to TRAIL and staurosporine treatments. Hence, USP35 is a hitherto unstudied DUB that 
regulates programmed cell death. This is consistent with the role of DUBAI, the D. 
melanogaster orthologue of mammalian USP35 and a related DUB, USP38 (Yang et al., 
2014). DUBAI protects cells from apoptosis by stabilising DIAP1, a major IAP in fly. 
Although details of apoptotic pathways differ to some extent between fly and mammals, we 
provide evidence that the function of DUBAI as an anti-apoptotic factor is evolutionary 
conserved, and in mammals carried out by USP35iso1. Consistent with anti-apoptotic roles, 
USP35 is amplified in a number of cancers, in which preferential translation of USP35iso1 
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would block apoptosis and ensure cancer cell survival. Interestingly, we observe that both 
USP35iso1 and USP35iso2 interact with a mammalian IAP, Birc6 (Bartke et al., 2004; Hao et 
al., 2004). It remains to be tested if this interaction plays a role in the observed anti- and pro-
apoptotic effects of USP35iso1 and USP35iso2, respectively. 
Consistent with distinct subcellular localisation our proteomic analysis indicates that USP35 
isoforms interact mostly with distinct sets of proteins. While USP35iso2 interacts 
predominantly with membrane-associated proteins, USP35iso1 binds preferentially 
cytoplasmic and centrosomal proteins. The latter finding suggests that USP35iso1 could 
participate, for example, in regulating cell division. Indeed, during the preparation of this 
manuscript it was reported that USP35 stabilises Aurora B, a key kinase regulating mitotic 
progression, and USP35 depletion results in cytokinesis defects (Park et al., 2018). At the 
moment it is unclear if and how the anti-apoptotic effect of USP35iso1 is related to its function 
in stabilising Aurora B. Intriguingly, Birc6 has also been implicated in cytokinesis (Pohl and 
Jentsch, 2008) and future studies will establish if the cytokinesis defects observed following 
USP35 depletion result solely from its effect on Aurora B or if USP35-Birc6 interaction also 
plays a role. 
Current proteomic datasets indicate that at least ~20,000 sites are modified with ubiquitin at 
steady state conditions in human cells (Kim et al., 2011; Udeshi et al., 2013), and it is 
therefore a massive endeavour for the relatively small number of ~100 DUBs to regulate 
them. Our results provide an important paradigm that alternative protein isoforms are of key 
importance for the expansion of DUB functionality and stress the need to study DUB 
isoforms. However, dissecting isoform-specific cellular functions is challenging and will 
require development of novel approaches such as the ability to selectively deplete only one 
isoform. We anticipate that studying functions of different isoforms in different experimental 
settings will reveal not only new DUB biology but also the true extent to which DUBs 
regulate cell physiology. 
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MATERIALS AND METHODS 
Materials 
Anti-USP35 antibodies were made to order by immunising sheep with glutathione S 
transferase (GST)-tagged recombinant fragments corresponding to USP35 residues: 1-437 
(AbN), 604-753 (Ab2) and 925-1018 (AbC). Anti-GST-reactive antibodies were 
subsequently depleted by passing the sera through a resin containing immobilised 
recombinant GST. These antibodies were used at 0.1 μg/ml for Western blotting and 2-3 μg 
per 1 mg of cell lysate for immunoprecipitation. The following commercial antibodies were 
used for Western blotting: rabbit anti-GFP (1:7500, Abcam, ab6556), rabbit anti-calnexin 
(1:1000, Cell Signalling Technology, 2679), mouse anti-α-tubulin (1:10 000, Cell Signalling 
Technology, 3873), mouse anti-caspase-8 (1:1000, Cell Signalling Technology, 9746), rabbit 
anti-caspase-8 (1:1000, Tocris, AF1650-SP), rabbit anti-cleaved caspase-3 (1:1000, Cell 
Signalling Technology, 9661), rabbit anti-BiP (1:1000, Cell Signalling Technology, 3177), 
rabbit anti-BAP31 (1:1000, ProteinTech, 11200-1-AP), mouse anti-CHOP (1:1000, Cell 
Signalling Technology, 2895P), rabbit anti-DR5 (1:1000, Cell Signalling Technology, 8074), 
mouse anti-GAPDH (1:10000, Abcam, ab8245). Mouse monoclonal anti-OPG tag antibodies 
(used at 1:1000 dilution) were a kind gift of Prof. Stephen High (University of Manchester) 
and were as published before (Adamus et al., 1991). Antibodies used for 
immunofluorescence microscopy were as follows: chicken anti-GFP (1:2000, Abcam, 
ab13970), rat anti-BAP31 (1:2000, Abcam, ab15044), rabbit anti-SPP (1:200, Bethyl 
Laboratories, A304-404A). 
Oleic acid-albumin complexes were purchased from Sigma Aldrich (O3008), LipidTox Deep 
Red Neutral Lipid Stain from Thermo Fisher Scientific (H34477), Endoglycosidase H from 
New England Biolabs (P0703), MTS assay kit from Promega (G3582), human recombinant 
TRAIL from Peprotech (310-04), zVAD-fmk from Enzo Life Sciences (ALX-260-020-
M001). GSK2606414 (5107), mevastatin (1526) and lovastatin (1530) were obtained from 
Tocris. 
 
Cell culture methods 
HeLa FlpIn T. rex and HEK293 FlpIn T. rex were obtained from ThermoFisher Scientific, 
HPAF-II cells from ATCC whilst U2OS FlpIn T. rex cells were as previously reported (Bago 
et al., 2014). All cell lines were regularly tested for contaminations. U2OS FlpIn T. rex, HeLa 
FlpIn T. rex and HEK293 FlpIn T. rex cells were grown in DMEM supplemented with 10% 
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(v/v) FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin. HPAF-II cells 
were grown in EMEM supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 1 mM sodium pyruvate and non-essential amino acids. 
Stable cell lines were generated by co-transfecting cells with pOG44 and plasmids encoding 
indicated proteins followed by selection in complete media containing 100 μg/ml 
hygromycin and 7.4 μg/ml blasticidin. Protein expression in stable cell lines was induced by 
addition of tetracycline to a final concentration of 200 ng/ml (U2OS FlpIn T.rex cells) or 1 
μg/ml (HEK293 FlpIn T.rex cells). 
DNA transfection was carried out using GeneJuice (Merck Millipore) according to 
manufacturer’s instruction. For cell treatment with oleic acid the media was replaced with 
DMEM supplemented with 0.3 mM oleic acid-BSA complexes (Sigma Aldrich), and cells 
were incubated for additional 24h. Cells were also treated with 20 μM MG132 for 7h, 50 
ng/ml recombinant human TRAIL (Peprotech) and 1 μM staurosporine for the times 
indicated.  
Mevastatin and lovastatin were used at 10 μM and added simultaneously with tetracycline-
mediated induction of USP35iso2. Cells were then incubated for 48h. Alternatively, parental 
cells were treated with statins for 2h, 100 nM thapsigargin was added and cells were further 
incubated for 18h. 
USP35 knock-out clones were generated by targeting exon 7 shared by all isoforms tested 
(sense gRNA gCATCCTTCAGGCCTTATTCA, antisense gRNA 
gTGACATAGCATGTGTTGCCC). Cells transfected with plasmids encoding these gRNAs 
and Cas9 were sorted into 96-well plates and clones derived from single cells screened by 
Western blotting. Candidate knock-out clones used for subsequent experiments were verified 
by sequencing of the targeted locus.   
 
Fluorescence microscopy 
Cells were grown on coverslips in 6-well plates and processed as described in figure legends. 
After washing with PBS, cells were fixed with 4% paraformaldehyde (PFA) for 15 min at 
RT. PFA was quenched by three consecutive washes with PBS supplemented with 100 mM 
glycine pH 8.0 (5 min each) and cells permeabilised with 0.1% (w/v) TX-100 for 5 min, RT. 
TX-100 was washed off with PBS and samples blocked with 1% (w/v) BSA in PBS for 15 
min, RT. Coverslips were stained with chicken anti-GFP (Abcam, 1:2000), rat anti-BAP31 
(Abcam, 1:2000) and rabbit anti-SPP (Bethyl Laboratories, 1:200) antibodies for 1h, RT. 
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Incubation with secondary antibodies (AlexaFluor conjugates, 1:750) was carried out for 30 
min and coverslips were mounted using ProLong Gold reagent. 
For lipid droplet staining cells were fixed, PFA quenched as described above and coverslips 
stained with LipidTox Deep Red (Life Technologies, 1:400) for 45 min, RT. 
Samples were imaged using DeltaVision fluorescence microscopes and images processes by 
deconvolution with Softworx software. 
 
Protein purification and in vitro assays 
The pFastBac expression vectors encoding full-length human GST-USP35 and GST-USP35 
C450A were used to generate recombinant baculoviruses using the Bac-to-Bac system 
(Invitrogen) following the manufacturer's protocol. These baculoviruses were used to 
infect Spodoptera frugiperda 21 cells (1.5 × 106/ml) at a multiplicity of infection of 5 and the 
infected cells were harvested 48 hours post-infection. GST-USP35 and GST-USP35 
C450A were purified on GSH-Sepharose and dialysed into 50 mM Tris-HCl pH 7.5, 0.1 mM 
EGTA, 150 mM NaCl, 270 mM sucrose, 0.03% Brij-35, 0.1% 2-mercaptoethanol, 1 mM 
benzamidine, 0.1 mM phenylmethylsulfonyl fluoride (PMSF). 
In vitro caspase cleavage assay was performed with Caspases Set III, human, recombinant 
Kit (#PK-RP577-K232, PromoKine), as per manufacturers instruction. In brief, 2 U of active 
recombinant human caspases were incubated with 4 μg purified human USP35C450A in buffer 
C (50 mM Hepes, pH 7.2, 50 mM NaCl, 0.1% (w/v) Chaps (3-[(3-cholamidopropyl)-
dimethylammonio)-1-propanesulfonate), 10 mM EDTA, 5% (w/v) Glycerol, 10 mM DTT) 
for 2 h at 37°C. 
DUB assays were carried out with 375 nM of USP35 and 733 nM of tetraUb of different 
linkage types (M1, K6, K11, K29, K33, K48 and K63) in 10 μl volume, in buffer D (50 mM 
Tris-HCl pH 7.5, 50 mM NaCl, 10 mM DTT) at 37°C for the times indicated. Reactions were 
quenched by adding LDS sample loading buffer. 
 
Protein crystallisation 
A construct of USP35 encoding amino acids S423-P944 with a deletion of E604-C753 
(codon optimized for expression in Sf9cells) was generated by gene synthesis (GeneArt, 
Thermo Fisher Scientific) and expressed from a pDEST20 vector (Thermo Fisher Scientific) 
in Trichoplusia ni insect cells (High Five, Thermo Fischer Scientific) in Insect-XPRESS 
medium (Lonza) as an N-terminal GST-fusion protein (cleavable by tobacco etch protease, 
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TEV). Cells were collected after 48 hours and homogenized by a Dounce tissue grinder in 
PBS, 10% glycerol, 5 mM DTT, pH 7.3, in the presence of protease inhibitors (Complete, 
Roche Applied Science).  After centrifugation at 11,000 x g (Beckman JA-10) the 
supernatant was batch-bound to a glutathione resin (Glutathione Sepharose, GE Healthcare). 
The resin slurry was washed with PBS, 10% glycerol, 5 mM DTT, pH 7.3. The fusion protein 
was cleaved with TEV protease (produced in-house) at 4°C overnight to remove the GST-tag. 
Resin was packed into a column while collecting protein in the flow-through. Protein eluting 
upon an additional wash step with buffer was combined with the flow-through. After a buffer 
exchange to 50 mM HEPES, 50 mM NaCl, 5 mM DTT, 5% glycerol, pH 7.3 on a HiPrep 
Desalting column (GE Healthcare) the protein was applied to cation- and anion-exchange 
columns coupled in series (Mono S(1st)-Mono Q(2nd) (GE Healthcare)), pre-equilibrated with 
50 mM HEPES, 50 mM NaCl, 5 mM DTT, 5% glycerol, pH 7.3. After separating the 
columns the recombinant protein was eluted from the Mono Q column by a gradient to 1 M 
NaCl. The eluted protein fraction was further purified on a gel filtration column (HiLoad 
Superdex S200, GE Healthcare) pre-equilibrated with 50 mM HEPES, 150 mM NaCl, 5 mM 
DTT, 5% glycerol, pH 7.3. The purified protein was concentrated to ~13 mg/ml and stored at 
-80 °C before further use. 
The purified protein was incubated with a 2-fold molar excess of a K48 linked-ubiquitin 
dimer for 30 minutes and crystallized with the vapour diffusion method. 1 μL of protein 
solution (10.5 mg/mL in 50 mM HEPES, 50mM NaCl, 5% Glycerol, 5mM DTT pH 7,3) was 
mixed with 1 μL of reservoir solution containing 100 mM HEPES pH 6.0 and 0.95 M 
ammonium sulfate at 20 °C. Data were collected on an in-house Cu sealed tube (Rigaku 
MicroMax-003) and processed using AutoProc (Vonrhein et al., 2011). The structure was 
solved by sulphur-SAD and automatically built using the AutoSol wizard of Phenix (Adams 
et al., 2010). The autobuilt model contained 378 of the 448 residues present in the 
asymmetric unit and was further refined using COOT (Emsley et al., 2010) and 
AutoBUSTER (Bricogne et al., 2016). See Table S2 for data collection and refinement 
statistics. 
 
Determination of membrane protein topology 
Potential transmembrane regions of USP351-1018 were predicted using ΔG predictor (Hessa et 
al., 2007) and TMpred (http://www.ch.embnet.org/software/TMPRED_form.html). 
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Protease protection assay was carried out using U2OS FlpIn cells induced with 200 ng/ml 
tetracycline for 48h in order to express the indicated proteins. Cells from a 15-cm dish were 
trypsinised, spun down and resuspended in 4 ml ice-cold KHM buffer (20 mM HEPES-
NaOH, pH 7.5, 110 mM KOAc, 2 mM Mg(OAc)2). Digitonin was added to a final 
concentration of 80 μg/ml and samples incubated on ice for 5 min, at which point they were 
diluted to 14 ml with KHM buffer and cells spun down. Cells were resupended in 5 ml ice-
cold HEPES buffer (90 mM HEPES-NaOH, pH 7.5, 50 mM KOAc), incubated for 10 min on 
ice and again isolated by centrifugation. Cells were resuspended in 1 ml ice-cold KHM 
buffer, counted and after pelleting resuspended in ice-cold KHM buffer. Proteolysis was 
carried out using equal number of cells expressing each construct in reactions supplemented 
with 0.5 mg/ml trypsin or 0.1 mM HCl used as a control. Reactions were performed for 1h on 
ice, stopped by the addition of soybean trypsin inhibitor (final concentration 1.25 mg/ml) and 
incubated for additional 10 min on ice. Sample buffer was added and samples denatured by 
heating at 70°C, for 10 min. 
In order to determine the topology using N-glycosylation as a read-out U2OS FlpIn cells 
transfected with USP35 constructs tagged with a peptide derived from bovine rhodopsin 
(SRMNGTEGPNFYVPFSNKTVD) were lysed and denatured in SDS sample buffer at 70°C 
for 10 min. 500 U of Endoglycosidase H (EndoH) was added and samples incubated for 5h at 
37°C.  
 
Subcellular fractionation 
Cells were washed with PBS, harvested and cell pellets resuspended in hypotonic buffer (10 
mM HEPES-NaOH, pH 7.5, 1.5 mM Mg(OAc)2, 10 mM KOAc, 0.5 mM DTT) 
supplemented with 1 mM AEBSF and complete protease inhibitor cocktail. After 10 min 
incubation on ice, cells were lysed by passing 10 times through a 27G needle. Cell debris and 
nuclei were pelleted by centrifugation (1000 x g, 10 min, 4°C) yielding a post-nuclear 
supernatant. Cytosolic and membrane fractions were separated by ultracentrifugation at 
100,000 x g, 15 min, 4°C.  
 
Proliferation assay 
U2OS FlpIn cell lines were seeded in full DMEM medium into a 96-well plate at 5 000 
cells/well (in total volume of 100 μl/well) and the next day protein expression was induced 
with 200 ng/ml tetracycline. Non-induced cells were analysed in parallel and each condition 
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was replicated in three separate wells. After 48h incubation 20 μl of the 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner 
salt (MTS) reagent (Promega) was added and plates incubated for 90 min in a humidified 
incubator at 37°C. Absorbance was measured at 490 nm and the values obtained for media 
only were used as controls and subtracted from the results obtained for the samples analysed. 
Results were processed with Microsoft Excel software and graphs prepared with Prism 7 
software. Three biological replicates were carried out. The same assay was used to estimate 
the viability of HEK293 FlpIn parental and knock-out clones in response to TRAIL treatment 
but cells were grown in DMEM without phenol red. 
 
Immunoprecipitation 
HeLa cells were treated with 1 μM staurosporine for the times shown in the presence of 20 
μM zVAD-fmk where indicated. Cell pellets were resuspended in buffer A (20 mM HEPES-
NaOH, pH 7.5, 110 mM KOAc, 2 mM Mg(OAc)2, 1 mM EGTA, 0.1% (w/v) NP-40) 
supplemented with 1 mM Na3VO4, 1 mM NaF, 25 mM iodoacetamide, 1 mM AEBSF and 
complete protease inhibitor cocktail. Samples were incubated for 30 min on ice followed by 
two rounds of snap freezing in liquid N2 and thawing at 30°C. Insoluble material was pelleted 
by centrifugation (16000 x g, 30 min, 4°C) and NaCl concentration adjusted to 150 mM. 
After pre-clearing with Protein G Agarose soluble fraction was subjected to 
immunoprecipitation with anti-USP35 antibodies or GFP trap resin (ChromoTek) for 2h at 
4°C. Beads were washed three times with buffer A supplemented with 150 mM NaCl, 
resuspended in SDS sample buffer and proteins denatured for 10 min at 70°C. For USP35 
immunoprecipitation from HPAF-II cells samples were processed as described above but 
cells were lysed in RIPA buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1% (w/v) NP-40, 
0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS) supplemented with 1 mM AEBSF, 
complete protease inhibitor cocktail and 0.1% benzonase. 
 
BioID 
BioID experiment was carried out essentially as described by (Coyaud et al., 2015) with 
slight modifications. Briefly, BirAR118G (BirA*) was fused to the C-terminus of human 
USP35iso1 and USP35iso2 in pcDNA5 FRT/TO and stable HEK293 FlpIn cell lines were 
generated. Experiments were performed with 4 x 150 cm2 dishes and expression was induced 
at ~60% confluency with 1µg/ml tetracycline (Sigma) for 24 h. Media was then replaced with 
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a fresh one supplemented with 50 μM biotin (Sigma) and cells were further incubated for 10 
h. Cells were washed twice with PBS, scraped, cell pellets snap frozen in liquid nitrogen and 
stored at -80°C. 
 
Cell pellets were lysed in 1 mL of modified RIPA lysis buffer (1% (v/v) NP-40, 50 mM Tris–
HCl, pH 7.5, 0.5% (w/v) sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
0.1% (w/v) SDS, 1:500 protease inhibitor cocktail (Sigma), with 250 U benzonase nuclease 
(Sigma)) in agitator for 1h at 4°C. The lysate was centrifuged for 30 min at 20,817 x g at 4°C 
and clarified supernatant incubated with 30 µl prewashed Streptavidin-Sepharose beads (GE 
Healthcare, catalog no. 17-5113-01) for 3 hr at 4°C. Beads were collected by centrifugation 
(400 x g, 2 min), washed twice with RIPA buffer (1 ml per wash), twice with TAP lysis 
buffer (50 mM HEPES-KOH, pH 8.0, 2 mM EDTA, 10% (v/v) glycerol, 100 mM KCl, 0.1% 
(v/v) NP-40), and four times with 50 mM ammonium bicarbonate (ABC; pH 8.0). Beads 
were then resuspended in 200 µl ammonium bicarbonate buffer and treated with 1µg of 
sequencing grade modified trypsin (Promega, V5113) for 12 h at 37°C with agitation. 
Additional 1 µg of trypsin was added after overnight digestion, samples were reduced with 5 
µl of 10 mM DTT and alkylated with 5 µl of 10 mM IAA. The supernatant containing the 
tryptic peptides was collected, de-salted using C18 micro-spin columns (The Nest Group, Inc.) 
and vacuum centrifuged. Peptides were re-suspended in 20 μl of 0.1% formic acid and 5 µl 
were used per MS run. 
 
In-gel digestion 
Protein bands were excised from Coomassie Brilliant Blue-stained SDS-PAGE gel, washed 
twice with water and twice with 50% acetonitrile. Proteins were reduced and alkylated with 
10 mM DTT and 55 mM iodoacetamide, respectively, in 100 mM ammonium bicarbonate 
and digested with 200 ng sequencing grade modified trypsin (Promega, V5113) for 14-16 h. 
Peptides were extracted twice with 50% acetonitrile and twice with 50% acetonitrile 
containing 2% formic acid and combined supernatants were dried using a Speedvac (Thermo 
Savant).  
 
Mass spectrometry 
The resulting peptides were analyzed by nano-Liquid chromatography (nLC, Dionex ultimate 
3000) coupled to mass spectrometry (MS, LTQ-Orbitrap Velos; Thermo Finnigan). Peptides 
were loaded on a pre-column (Acclaim pepmap, C18, 100Å, 100µm; Thermo) at 5 μl/min 
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flow rate and resolved on analytical column (Acclaim PepMap C18, 2 µm, 100 Å, 75 µm x 50 
cm), with 185 min gradient program, buffer B (90% acetonitrile, 3% DMSO, 0.08% formic 
acid (v/v)) and buffer A (2% acetonitrile, 3% DMSO, 0.1% formic acid, (v/v)) of buffer B 
ranging from 1 to 45%. Data was acquired in data dependent mode, a parent ion scan was 
performed in the Orbitrap, using a resolving power of 60000; at m/z 400. Simultaneously, 
CID was performed in ion trap activation time of 10 ms, with top 15 precursor ions. Protein 
identification was carried out using Sequest search algorithm against Uniprot database by 
selecting semi-tryptic enzymatic digestion option. 
 
Protein identification 
The MS raw files were searched using MaxQuant (version 1.5.8.3) (Cox and Mann, 2008), 
with the integrated Andromeda search engine. For the identification of peptides and proteins 
the UniProt human FASTA database (March 2015) was used with the FDR < 0.01.  Oxidized 
methionine (M) and acetylation (protein N-term) were set as variable modifications and 
carbamidomethyl (C) as fixed modification. MaxQuant LFQ (Label free quanti- tation) was 
enabled with the stand ‘match between runs’. The bona fide USP35 interacting proteins were 
identified with spectral counting as input for SAINTexpress (Significance Analysis of 
INTeractome) (Teo et al., 2014) with BFDR value of 2%. The resulting high confidence 
interacting proteins (HCIPs) were then subjected to DAVID enrichment analysis for cell 
compartment (Huang da et al., 2009). 
 
Bioinformatics analysis 
To analyse isoform expression in primary tumours, the TCGA transcript expression levels 
have been downloaded from UCSC Xena (http://xena.ucsc.edu/) version 2016-04-12. RNA-
Seq reads were processed with the RSEM tool based on Gencode v23 transcript annotation. 
TPM expression values have been extracted from the RSEM result files and transformed to 
log2(tpm+0.001) values. 
Expression of USP35 isoforms in selected cell lines was addressed by submitting the cell 
lines to Illumina Truseq RNA-Seq sequencing (poly-A selection) on an Illumina HiSeq 
instrument. Reads were processed with cufflinks version 2.0.2-foss-2015a with parameters -u 
--max-bundle-frags 10000000 --max-bundle-length 10000000 --no-effective-length-
correction --compatible-hits-norm --max-frag-multihits 1. Ensembl v70 (hg19) gene 
annotation was used to determine the transcript expression levels. FPKM expression values 
were extracted from the cufflinks result files for all USP35 isoforms. 
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Accession code 
Coordinates and structure factors have been deposited in the Protein Data Bank under 
accession code 5TXK. 
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FIGURE LEGENDS  
Figure 1. USP35 is an active, promiscuous DUB. 
A. (Left panel) Organisation of USP35 transcripts encoding isoforms presented in this study. 
Orange and grey boxes represent exons and non-coding regions, respectively. Exon numbers 
are given. (Right panel) Domain organisation of USP35 isoforms. The USP domain of 
USP35 is shown together with catalytic Cys450 and an unstructured insertion spanning 
residues 604-753. HEAT repeat motif predicted based on the crystal structure of the N-
terminus of a related protein, USP38 (PDB: 4RXX), and protein regions used to generate 
anti-USP35 antibodies are indicated. Uniprot accession numbers of each isoform are shown 
on the left.  
 
B. Purified, recombinant full-length human USP35 (375 nM) was incubated with 
tetraubiquitins of defined linkage types (733 nM) at 37°C for the indicated times. Reactions 
were resolved by SDS-PAGE followed by silver staining of the gel.  
 
C. Crystal structure of the fragment of human USP35 (residues 423-944) lacking the insertion 
region (residues 604-753) and complexed with ubiquitin is presented. The subdomains 
thumb, palm and fingers are shown in wheat, light pink and yellow, respectively, whilst the 
non-covalently bound distal ubiquitin is in green. The dashed line has been used to show the 
disordered regions. The co-ordinated zinc can be seen as a black sphere in the finger 
subdomain. A potential binding site of proximal ubiquitin is indicated. Close up views show 
the catalytic centre and selected residues mediating USP35-ubiquitin interactions.  
 
Figure 2. USP35 isoforms localise to distinct intracellular compartments. 
A. U2OS FlpIn inducible cells expressing USP35 isoforms bearing a C-terminal GFP tag 
were fixed with paraformaldehyde (PFA) and stained with anti-GFP antibody. Protein 
localisation was examined by fluorescence microscopy.  
 
B. As in (A) but samples were simultaneously stained with anti-GFP and anti-BAP31 ER 
marker antibodies.  
 
C. U2OS FlpIn USP35iso2 cell line was left untreated or loaded with 0.3 mM oleic acid for 
16h, at which point expression of iso2 was induced. Following an 8h incubation cells were 
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fixed with PFA and stained with LipidTox Deep Red. LipidTox staining and intrinsic GFP 
fluorescence was analysed by microscopy.  
 
D. Expression of USP35245-432 with a C-terminal GFP tag in stably transfected U2OS FlpIn 
cells was induced with tetracycline.  Cells were fixed, stained with anti-GFP and anti-BAP31 
antibodies, and samples analysed by immunofluorescence microscopy. Scale bar, 15 μm 
(panels A, B and D) and 5 μm (panel C).  
 
Figure 3. USP35 isoform 2 is a novel integral membrane DUB. 
A. Expression of the indicated variants of USP35 in U2OS FlpIn cells was induced with 
tetracycline, cells were semi-permeabilised with digitonin and trypsin or buffer control 
added. Samples were incubated for 1h on ice, resolved by SDS-PAGE and immunoblotted 
with anti-GFP antibody. Immunoblotting for calnexin (CNX) was used to validate the assay. 
Red dot indicates the protease-resistant USP35 fragment whilst the arrow marks a protein 
species most likely corresponding to high amount of trypsin used in the assay.  
 
B. U2OS FlpIn cells were transfected with USP35iso2 tagged at the N- or C-terminus with a 
peptide derived from bovine rhodopsin (OPG) that contains two N-glycosylation sites. Cells 
were lysed, samples incubated with endoglycosidase H (EndoH) and resolved by SDS-
PAGE. Results were visualised by immunoblotting with an anti-rhodopsin antibody. 
Numbers on the left indicate the number of N-glycans added to USP35iso2 whilst arrowheads 
an EndoH-sensitive truncated product of the N-terminally tagged iso2.  
 
C. As in (B) but USP35 truncation spanning residues 270-432 was used. Numbers on the left 
indicate the number of N-glycans attached to the USP35 fragment.  
 
D. As in (B) but the indicated truncations of USP35 bearing an N-terminal OPG tag were 
used. Note that iso2 corresponds to “270-end” variant. Red circles represent N-glycosylated 
species. 
 
E. Experimentally validated topology of USP35iso2. Amino acid sequence and conservation of 
the predicted transmembrane region is shown. “*” indicates fully conserved residues, “:” 
conserved residues of “strong groups” and “.” conserved residues of “weak groups” based on 
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ClustalX. The sequences used were as follows: NP_065849.1 (H. sapiens), NP_001170883.1 
(M. musculus), XP_015136357.1 (G. gallus), XP_002936594.2 (X. tropicalis) and 
NP_725167.1 (D. melanogaster). 
 
F. HPAF-II cells were lysed in the absence of detergent, post-nuclear supernatant (PNS), 
cytosolic and membrane fractions isolated and endogenous USP35 identified by 
immunoblotting using anti-USP35 antibody raised against the extreme C-terminus of the 
protein. Lysates of HPAF-II cells transfected with untagged USP35 isoforms 1 and 2 were 
used as markers for the electrophoretic migration of USP35 isoforms. Calnexin (CNX) and 
tubulin were used as markers for the membrane and cytosolic fractions, respectively.  
 
G. HPAF-II cells were lysed in RIPA buffer and USP35 immunoprecipitated using the 
indicated antibodies. Samples were resolved by SDS-PAGE and immunoblotted with anti-
USP35 antibody recognising the C-terminal region of the protein. Ectopically expressed, 
untagged USP35 isoforms were used as markers for the electrophoretic mobility.  
 
 
Figure 4. USP35 isoform 2 overexpression induces ER stress and apoptosis. 
A. Expression of USP35iso2 tagged at the C-terminus with GFP was induced in U2OS FlpIn 
cells with tetracycline for 48h. Cells were fixed with PFA, co-stained with anti-GFP, anti-
BAP31 and anti-SPP (signal peptide peptidase) antibodies and analysed by microscopy. Scale 
bar, 15 μm.  
 
B. Expression of USP35iso2 or a control ER-localised construct GFP-b5 was initiated by 
adding tetracycline to U2OS FlpIn cell lines. After 48h cells were lysed, samples resolved by 
SDS-PAGE and immunoblotted using antibodies against the indicated proteins. cl. BAP31 – 
cleaved BAP31.  
 
C. As in (B) but the cell lines were seeded into a 96-well plate and 48h post-induction MTS 
proliferation assay was performed. The values on the Y axis represent the ratio of absorbance 
read for induced to non-induced cells. Statistical significance was calculated using a one-way 
Anova test. Error bars indicate standard errors of mean with N=3 biological replicates, 
****P<0.0001, ***P = 0.0002. 
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D. USP35iso2 tagged at the C-terminus with GFP was expressed in inducible U2OS FlpIn cell 
line for 24h in the presence of 5 μM GSK2606414 or DMSO control. Cells were lysed, 
samples resolved by SDS-PAGE and immunoblotted using antibodies against the indicated 
proteins.  
 
E. As in (B) but HeLa FlpIn cell lines induced to express GFP-b5 or USP35iso2 were used.  
 
F. Expression of USP35iso2 bearing a C-terminal GFP tag was induced in U2OS FlpIn cell 
line. Levels of the GFP-tagged protein and upregulation of BiP were monitored at the 
indicated time points by immunoblotting cell lysates with antibodies against the indicated 
proteins. 
 
G. As in (B) but U2OS FlpIn cells stably transfected with GFP-USP19 were used as a 
control. “++” indicates higher concentration of tetracycline used for GFP-USP19 expression. 
 
Figure 5. Inhibition of cholesterol biosynthesis blocks USP35iso2 induced ER stress. 
A. U2OS FlpIn parental cells were pretreated with 10 μM mevastatin or lovastatin for 2h and 
incubated with 100 nM thapsigargin for additional 18h (lanes 2-4). In parallel, U2OS FlpIn 
cells were induced to express USP35iso2 for 48h in the presence of 10 μM statins. Samples 
were analysed as in Fig 4B. Control samples represent cells without thapsigargin treatment or 
USP35iso2 induction. 
 
B. Samples after statin treatment and USP35iso2 induction as shown in (A, lanes 6-9) were 
analysed by quantitative Western blotting and fold change of BiP induction relative to control 
plotted. Statistical significance was calculated using a one-way Anova test. Error bars 
indicate standard errors of mean with N=3 biological replicates, ****P = 0.0001, NS, not 
significant. 
 
C. As in Fig 4B but U2OS FlpIn cells expressing indicated variants of USP35iso2 in a 
tetracycline-inducible manner were used.  
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D. U2OS FlpIn cells expressing indicated variants of USP35iso2 for 24h were subjected to 
subcellular fractionation followed by Western blotting analysis. 
 
E. U2OS FlpIn cells were induced to express indicated GFP-tagged variants of USP35iso2 or 
GFP-b5 for 24h. Cells were lysed, GFP-tagged proteins and their binding partners recovered 
and samples analysed by Western blotting against the indicated proteins. 
 
F. Indicated USP35 fragments (numbering based on iso1) were tagged at the C-terminus with 
GFP and at the N-terminus with the first 61 residues of SPP encompassing its first 
transmembrane region (TM1). USP35iso2 and GFP fused to such N-terminal fragment of SPP 
served as controls. Cells were treated and samples processed as described for Fig 4B. 
 
Figure 6. USP35 isoform 1 is an anti-apoptotic protein. 
A. Expression of the indicated isoforms of USP35 in stably transfected U2OS FlpIn cell lines 
was carried out for 48h. Cells were lysed, samples resolved by SDS-PAGE and 
immunoblotted with antibodies against the indicated proteins. cl. BAP31 – cleaved BAP31.  
 
B. HEK293 FlpIn stably transfected cell lines were induced to express FLAG-tagged 
USP35iso1 wild-type protein, its catalytically-inactive variant or empty vector control. 24h 
post-induction cells were treated with 50 ng/ml TRAIL. Cells were lysed, samples resolved 
by SDS-PAGE and processing of caspase-8 analysed by immunoblotting.  
 
C. HEK293 FlpIn parental cell line and two USP35 knock-out clones were treated with 50 
ng/ml TRAIL and samples were analysed as for (B).  
 
D. As in (C) but the cell lines were seeded into a 96-well plate, incubated with 50 ng/ml 
TRAIL for the indicated times and MTS proliferation assay was performed. The values on 
the Y axis represent the ratio of absorbance read for treated to untreated cells. Error bars 
indicate standard errors of mean with N=3 biological replicates.  
 
E. HEK293 FlpIn parental cell line and two USP35 knock-out clones were treated with 
increasing concentrations of staurosporine for 24h. Cells were lysed and samples analysed by 
immunoblotting with an antibody against cleaved caspase-3.  
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F. HeLa cells were transfected with wild-type USP35iso1 or a variant with Asp743 substituted 
for Ala, both tagged at the C-terminus with a GFP tag. 24h post-transfection 1 μM 
staurosporine was added and cells incubated for the indicated time. Cells were lysed, samples 
resolved by SDS-PAGE and analysed by immunoblotting against the indicated proteins. 
 
Figure 7. Isoform-specific interactome of USP35. 
A. HEK293 FlpIn cells expressing USP35iso1 or USP35iso2 tagged at their C-terminus with 
BirAR118G were induced for 24h, biotinylated proteins recovered on Streptavidin Sepharose, 
identified by mass spectrometry and subjected to SAINT analysis and DAVID GO analysis. 
Green bars show GO terms for the percentage of genes identified whilst red line indicates -
log10 p value.  
 
B. Isoform-specific and shared interacting partners are shown. 
 







